Literature DB >> 19336547

Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan.

Wan-Lun Hsu1, Jen-Yang Chen, Yin-Chu Chien, Mei-Ying Liu, San-Lin You, Mow-Ming Hsu, Czau-Siung Yang, Chien-Jen Chen.   

Abstract

This study aimed to assess independent effects of EBV and cigarette smoking on nasopharyngeal carcinoma, which have never been assessed in long-term follow-up studies. A cohort of 9,622 men was enrolled from 1984 to 1986. Blood samples collected at study entry were tested for antibodies against EBV antigens (anti-EBV) viral capsid antigen immunoglobulin A and DNase. The cigarette smoking habit was inquired through questionnaire interview. Newly developed nasopharyngeal carcinoma cases were ascertained through computerized linkage with national cancer registry profile. Cox's proportional hazard regression analysis was used to estimate multivariate-adjusted hazard ratio with its 95% confidence interval (95% CI). During the follow-up of 173,706 person-years, 32 pathologically confirmed nasopharyngeal carcinoma cases were identified >1 year after recruitment. Increasing serum levels of anti-EBV viral capsid antigen immunoglobulin A and DNase were significantly associated with nasopharyngeal carcinoma risk in a dose-response relationship. The multivariate-adjusted hazard ratio (95% CI) of developing nasopharyngeal carcinoma for low and high antibody levels compared with seronegatives was 9.5 (2.2-40.1) and 21.4 (2.8-161.7), respectively, for anti-EBV viral capsid antigen immunoglobulin A (P < 0.001 for trend), and 1.6 (0.5-4.6) and 16.0 (5.4-47.1), respectively, for anti-EBV DNase (P < 0.001 for trend). The shorter the time interval between study entry and nasopharyngeal carcinoma diagnosis, the higher was the proportion of anti-EBV viral capsid antigen immunoglobulin A among nasopharyngeal carcinoma patients. The multivariate-adjusted hazard ratio (95% CI) was 3.0 (1.3-7.2) for > or =30 pack-years of cumulative cigarette smoking compared with <30 pack-years as the reference. The longer and heavier the cigarette smoking habit, the higher was the nasopharyngeal carcinoma risk. Anti-EBV viral capsid antigen immunoglobulin A, anti-EBV DNase, and long-term heavy cigarette smoking are independent nasopharyngeal carcinoma risk predictors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336547     DOI: 10.1158/1055-9965.EPI-08-1175

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  35 in total

Review 1.  Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted between 1979 and 2011.

Authors:  Wen-Qiong Xue; Hai-De Qin; Hong-Lian Ruan; Yin Yao Shugart; Wei-Hua Jia
Journal:  Am J Epidemiol       Date:  2013-06-19       Impact factor: 4.897

2.  Blood cadmium burden and the risk of nasopharyngeal carcinoma: a case-control study in Chinese Chaoshan population.

Authors:  Lin Peng; Xiaoling Wang; Xia Huo; Xijin Xu; Kun Lin; Jingwen Zhang; Yue Huang; Kusheng Wu
Journal:  Environ Sci Pollut Res Int       Date:  2015-04-23       Impact factor: 4.223

3.  Relationships between genetic polymorphisms in inflammation-related factor gene and the pathogenesis of nasopharyngeal cancer.

Authors:  Yan-Li Qu; Hong Yu; Yan-Zhi Chen; Yu-Xia Zhao; Guang-Jun Chen; Lu Bai; Dan Liu; Hong-Xin Su; He-Tong Wang
Journal:  Tumour Biol       Date:  2014-06-22

4.  Viral infections associated with oral cancers and diseases in the context of HIV: a workshop report.

Authors:  D J Speicher; V Ramirez-Amador; D P Dittmer; J Webster-Cyriaque; M T Goodman; A-B Moscicki
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

5.  Familial tendency and risk of nasopharyngeal carcinoma in taiwan: effects of covariates on risk.

Authors:  Wan-Lun Hsu; Kelly J Yu; Yin-Chu Chien; Chun-Ju Chiang; Yu-Juen Cheng; Jen-Yang Chen; Mei-Ying Liu; Sheng-Ping Chou; San-Lin You; Mow-Ming Hsu; Pei-Jen Lou; Cheng-Ping Wang; Ji-Hong Hong; Yi-Shing Leu; Ming-Hsui Tsai; Mao-Chang Su; Sen-Tien Tsai; Wen-Yuan Chao; Luo-Ping Ger; Peir-Rong Chen; Czau-Siung Yang; Allan Hildesheim; Scott R Diehl; Chien-Jen Chen
Journal:  Am J Epidemiol       Date:  2010-12-10       Impact factor: 4.897

6.  Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization.

Authors:  Zhiwei Liu; Kelly J Yu; Anna E Coghill; Nicole Brenner; Su-Mei Cao; Chien-Jen Chen; Yufeng Chen; Denise L Doolan; Wan-Lun Hsu; Nazzarena Labo; Jaap M Middeldorp; Wendell Miley; Julia Simon; Cheng-Ping Wang; Tim Waterboer; Denise Whitby; Shang-Hang Xie; Weimin Ye; Allan Hildesheim
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

7.  Human papillomavirus and WHO type I nasopharyngeal carcinoma.

Authors:  Emily J Lo; Diana Bell; Jason S Woo; Guojun Li; Ehab Y Hanna; Adel K El-Naggar; Erich M Sturgis
Journal:  Laryngoscope       Date:  2010-10       Impact factor: 3.325

Review 8.  Nasopharyngeal carcinoma among the Bidayuh of Sarawak, Malaysia: History and risk factors.

Authors:  Reagan Entigu Linton; Maelinda Daker; Alan Soo-Beng Khoo; Diana Chung Yiing Choo; Mignon Viljoen; Paul M Neilsen
Journal:  Oncol Lett       Date:  2021-05-06       Impact factor: 2.967

9.  Smoking and nasopharyngeal cancer: individual data meta-analysis of six prospective studies on 334 935 men.

Authors:  Jia Huang Lin; Chi Pang Wen; Chao Qiang Jiang; Jian-Min Yuan; Chien Jen Chen; Sai Yin Ho; Wayne Gao; Weisen Zhang; Renwei Wang; Yin-Chu Chien; Lin Xu; Xifeng Wu; Ya Li Jin; Woon-Puay Koh; Wan-Lun Hsu; Feng Zhu; Christopher Wen; Tong Zhu; June Han Lee; Zhi-Ming Mai; Maria Li Lung; Tai-Hing Lam
Journal:  Int J Epidemiol       Date:  2021-07-09       Impact factor: 7.196

10.  The synergistic effect of chemical carcinogens enhances Epstein-Barr virus reactivation and tumor progression of nasopharyngeal carcinoma cells.

Authors:  Chih-Yeu Fang; Sheng-Yen Huang; Chung-Chun Wu; Hui-Yu Hsu; Sheng-Ping Chou; Ching-Hwa Tsai; Yao Chang; Kenzo Takada; Jen-Yang Chen
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.